Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

204902 Complement C5a des-Arg, Human

Complement C5a des-Arg, Human, is a native, single chain glycopeptide (73 aa). Once produced, C5a is converted to C5a des-Arg upon removal of the C-terminal arginine by serum carboxypeptidase N.

Complement C5a des-Arg, Human : FDS (Fiches de données de sécurité), certificats d’analyse (CoA) et de qualité (CoQ), dossiers, brochures et autres documents disponibles.
204902
Purchase on Sigma-Aldrich

Aperçu

Replacement Information

Products

RéférenceConditionnement Qté
204902-30UG Ampoule plast. 30 μg
Description
OverviewNative, human des-Arg C5a complement component. Single chain glycopeptide composed of 73 amino acids. Once the C5a glycopeptide has been produced in human plasma or serum, it is rapidly converted to C5a des-Arg upon removal of the C-terminal arginine by the endogenous serum carboxypeptidase N. Unlike the C3a des-Arg peptide, C5a des-Arg retains significant levels of its biological activities. Thus, C5a des-Arg has been shown to exhibit inflammatory cell chemotaxis, smooth muscle contraction, and leukotriene release from guinea pig lung.
Catalogue Number204902
Brand Family Calbiochem®
References
ReferencesWebster, R.O., et al. 1980. Immunopharmacology 1, 201.
McCarthy, K. and Henson, P.M. 1979. J. Immunol. 123, 2511.
Product Information
FormLiquid
FormulationIn 120 mM NaCl, 10 mM HEPES, pH 7.2.
Quality LevelMQ100
Applications
Biological Information
Purity≥90% by SDS-PAGE
SourcePrepared from plasma of individuals that have been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
Concentration Label Please refer to vial label for lot-specific concentration
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Dry Ice Only
Toxicity Standard Handling
Storage ≤ -70°C
Avoid freeze/thaw Avoid freeze/thaw
Do not freeze Ok to freeze
Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Référence GTIN
204902-30UG 04055977219869

Documentation

Complement C5a des-Arg, Human FDS

Titre

Fiche de données de sécurité des matériaux (FDS) 

Complement C5a des-Arg, Human Certificats d'analyse

TitreNuméro de lot
204902

Références bibliographiques

Aperçu de la référence bibliographique
Webster, R.O., et al. 1980. Immunopharmacology 1, 201.
McCarthy, K. and Henson, P.M. 1979. J. Immunol. 123, 2511.
Fiche technique

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision27-September-2010 RFH
DescriptionNative, human des-Arg C5a complement component. Single chain glycopeptide composed of 73 amino acids. Once the C5a glycopeptide has been produced in human plasma or serum, it is rapidly converted to C5a des-Arg upon removal of the C-terminal arginine by the endogenous serum carboxypeptidase N. Unlike the C3a des-Arg peptide, C5a des-Arg retains significant levels of its biological activities. Thus, C5a-des-Arg has been shown to exhibit inflammatory cell chemotaxis, smooth muscle contraction, and leukotriene release reactions from guinea pig lung.
FormLiquid
FormulationIn 120 mM NaCl, 10 mM HEPES, pH 7.2.
Concentration Label Please refer to vial label for lot-specific concentration
SourcePrepared from plasma of individuals that have been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
Purity≥90% by SDS-PAGE
Storage Avoid freeze/thaw
≤ -70°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
Toxicity Standard Handling
ReferencesWebster, R.O., et al. 1980. Immunopharmacology 1, 201.
McCarthy, K. and Henson, P.M. 1979. J. Immunol. 123, 2511.